1. MECHANISMS OF NEURODEGENERATION

A.   Macromolecular interactions and Neurodegeneration

#		
1.	Public health. Therapeutic strategies for the prevention and tratment of neurodegenerative disease. Molecular basis of amyloid aggregation	Pier Luigi San Biagio pierluigi.sanbiagio@pa.ibf.cnr.it
2.	Protein conformational transitions that trigger the aggregation processes associated to neurodegenerative diseases : a nanotechnological approach	Bruno Samorì bruno.samori@unibo.it
3.	Myelin proteins and demyelinating deseases	Eugenia Polverini eugenia.polverini@unipr.it
4.	Conformational transitions of proteins from native to amyloid form	Roberto de Renzi mariagrazia.bridelli@unipr.it
5.	Role of altered composition of plasma membrane complex lipids in lipid-protein interactions, membrane organization and neurodegeneration	Sandro Sonnino Sandro.sonnino@unimi.it
6.		Angelo Poletti Angelo.poletti@unimi.it
7.	Optical and biomolecular methods for the functional investigation of neural circuits in vivo	Antonio Malgaroli Antonio.malgaroli@hsr.it Gian Giacomo Consalez Giacomo.consalez@hsr.it
8.	Molecular mechanisms in neurotransmission: effects in neuron and glia phenotypes in synaptic efficiency and synapropathy	Flavia Valtorta Valtorta.flavia@hsr.it
9.	Presynaptic molecular machinery regulationg glutamate release an pathophysiological mechanism in amyotrophic lateral sclerosis	Maurizio Popoli Maurizio.popoli@unimi.it
10.	Toward exploiting the screening potential of miRNome for the identification of genes and pathways involved in neurodegenerative disorders	Daniela Tardito Daniela.tardito@unimi.it
11.	Stress, neuroplasticity and susceptibility to neurodegenerative and psychiatric disorders.	Marco Andrea Riva M.riva@unimi.it
12.	Interaction af Abeta and alpha-synuclein with the cytoskeleton	Fabio Benfenati – Evelina Chieragatti Giuseppe Ronzitti – Anako Tsushima Fabio.benfenati@iit.it
13.	Mecanisms of neurodegeneration and enhancement of adult neurogenesis to improve cognitive functions in down syndrome	Fabio Benfenati – Andrea Contestabile – Diego Ghezzi – laura Gasparini Fabio.benfenati@iit.it
14.		Luigia Trabace – Tucci- Colaianni-Morgese-Zotti trabace@unifg.it
15.		Salmona Mario - Forloni Mario.salmona@marionegri.it

B.   Neurotoxic stimuli

#		
1.	CSF Glycomics in AD and other neurodegenerative	Domenico Garozzo

	disease	domenico.garozzo@cnr.it
2.	Intracellular signalling during neurodegenerative events friggere upon APP overexpression	Maurizio Taglialatela m.taglialatela@unimol.it
3.	Effect of Age and neurodegenerative disorders in central neurotrasmission: focus on neurotrasmitter relase from neuron and glia	Mario Marchi marchi@pharmatox.unige.it
4.	Glutamate release and excitoxicity as targets for new neuropreotective strategies in animal models of amytrophic lateral sclerosis	Bonanno Gianbattista bonanno@pharmatox.unige.it
5.	Novel cytotoxic pathways in Alzheimer's disease	Bruno Bonetti Bruno.benetti@univr.it
6.	Basic Research: developing competitive in " vitro" and "vivo" models to study Alzheimer's disease	Francesca Ruberti f.ruberti@inmm.cnr.it
7.	Evaluation of mesenchymal stell cells (MSCs) effect in Alzheimer's disease rat models competitive in " vitro" and "vivo" studies	Mariarosaria Miloso mariarosaria.miloso@unimib.it
8.	New Tratment strategies (Neurodegeneration and Neuroprotection)	Patrizia Hrelia Patrizia.hrelia@unibo.it
9.	Pathways leading to tau pathology – Role of nuclear tau in neurodegeneration in fronto-temporal dementia	Fabrizio Tagliavini ftagliavini@istituto-besta.it
10.	The physiologic and pathologic effect of Beta-amyloid 42	Massimo Tabaton mtabaton@neurologia.unige.it
11.	Cholesterol and amyloid-beta: is there a relation? - Study of the non muscle myosin II involvement in the processing of the amyloid precursor protein (APP) - Specific type 4 phosphodiestrerase inhibitors and their impact on the production af amyloid-beta	Roberta Ricciarelli ricciarelli@medicina.unige.it
12.	Age-related neurodegenerative disorders associated with proteotoxic stress	Patrizia Guarneri guarneri@ibim.cnr.it
13.	Basic research - Genetic susceptibility to Alzheimer disease and genome wide association studies - Biobanking	Dario Finazzi finazzi@med.unibs.it
14.	Neurotoxic stimuli, synaptic dysfunction	Calro Sala c.sala@in.cnr.it
15.		Cristina Limatola Cristina.limatola@uniroma1.it
16.		Andrea Ballabio ballabio@tigem.it
17.	Phatogenesis and therapeutic targets for SBMA	Fabio Benfenati – Mara Pennuto – Chiara Scaramuzzino Fabio.benfenati@iit.it
18.		Luigi Zecca luigi.zecca@itb.cnr.it

C. Neuro inflammation

1.	Neuroimmunology af Alzheimer's disease	Marco Cosentino marco.cosentino@unisubria.it

2. Role of inflammation mechanisms in neurodegenerative diseases	Gabriela Constantin gabriela.constantin@univr.it
3. Regional vulmerability of the brain to neurodegeneration and immune regulatory mechanisms	Marina Bentivoglio marinabentivoglio@univr.it
4. Neurotoxic stimuli	Michela Matteoli Michela.matteoli@unimi.it
5. Gender and hormonal/endocrine signals in neuroinflammation role in alzheimer's disease and brain ageing	Elisabetta Vegeto Elisabetta.vegeto@unimi.it
6. Role of pro-and anti- inflammatory cytokines in the prognosis and progression of neurodegenerative diseases	Barbara Viviani Barbara.viviani@unimi.it
7. Study of the role of pro-inflammatory chemokines in neuroinflammatory disorders and analysis of the therapeutic potential of chemokine synthesis inhibitors	Claudio Milanese c.milanese@angelini.it
8.	Luisa Minghetti luisa.minghetti@iss.it

D. Oxidative Stress and neurodegeneration

1. In "*vivo*" models for differentiation and survival of neural progenitor cells, towards the Dopamine and the GABA lineages	Giorgio Merlo gmerlo@dti.telethon.it
2. Indagine di meccanismi molecolari alla base della malattia di Parkinson	Marco Bisaglia marco.bisaglia@unipd.it
3. Mitochondria, apoptosis and neurodegeneration: characterization of mitochondrial dysfunction in neurodegenerative diseases - Characterization of the molecular mechanisms underlying aging, cell senescence and neurodegenerative diseases	Antonella Bobba a.bobba@ibbe.cnr.it
4. Structural organization of the mitochondrial respiratory chain, generation of reactive oxygen species and neurodegeneration	Giorgio Lenaz giorgio.lenaz@unibo.it
5. Post-genomic biochemestry of neurodegenerative diseases	Annalisa Santucci santucci@unisi.it

E. Trophic factors involvement in the neurodegeneration process

1. Towards an NGF- based therapy for Alheimer's disease	Antonino Cattaneo a.cattaneo@ebri.it
2. Mechanisms imlicating BDNF activity in the control of adult neurogenesis	Marco Canossa marco.canossa@unibo.it

F. Endocrine and Metabolic Factors

1.	Membrane lipid-Protein interactions: new opportunities for human health and disease	Mauro Maccarrone mmaccarrone@unite.it
2.	miRNA as sensors of neuronal stress and modulators of synaptic plasticità and memory deficits	Paola Fragapane paola.fragapane@uniroma1.it
3.	Developing competitive animal models to study Alzheimer's disease	Roberto Rimondini roberto.rimondini@unibo.it
4.	Developing a non genetic model of pre symptomatic AD to hypothesize novel cell metabolic pathways and therapeutic targets	Stefano Loizzo stefano.loizzo@iss.it
5.	Genetic susceptibility to Alzheimer's disease Alzheimer's disease in women: AD as a gender disease	Rosa Maria Corbo rosamaria.corbo@uniroma1.it
6.	Pluripotent, multi-functionally protective and homeostatic animo acids, di-and tripeptides in Alzheimer's disease and the role of the brain Peptide/Histidine Trasporter 1 (PHT1)	Tiziano Verri tiziano.verri@unisalento.it
7.	Genetic susceptibility to Alzheimer's disease (Epigenetic maks of susceptibility to Alzheimer disese)	Lucia Migliore l.migliore@geog.unipi.it
8.	Role of altered lipid and cholesterol metabolism in neurodegenerations	Laura Colombaioni laura.colombaioni@in.cnr.it
9.		Roberto Cosimo Melcangi Roberto.melcangi@unimi.it
10.	Selective Alzheimer Disease Indicator -1 (Seladin-ò1): a liker between cholesterol, oxidative stress and Alzheimer's disease	Roberto Maggi Roberto.maggi@unimi.it
11.	Neurodegenerative disorders and therapeutic strategy	Anna Petroni Anna.petroni@unimi.it
12.	Nuclear receptors, coregulators, neuroactive steroids and epigenetics in neurodegenerative disease associated to metabolic disorders	Donatella Caruso Donatella.caruso@unimi.it

G. Cell interactions

1.	The Astrocyte, not just a Bystander in Alzheimer's disease	Ubaldo Armato ubaldo.armato@univr.it
2.		Giovanni Savettieri giosav@unipa.it
3.	Synapse and Amyloid-beta: effects on astrocyte processes, nerve terminals and network synaptic activity	Manuela Marcoli marcoli@pharmatox.unige.it
4.	Alzheimer's disease, Ageing	Luciano Domenici domenici@in.cnr.it

H. Intracellular Traffiking

1.	Membrane traffic and neurodegenerative diseases: role of Rab proteins and their effectors	Cecilia Bucci cecila.bucci@unisalento.it

2. Basic research. Neurodegenerative diseases	Paolo Macchi macchi@science.unitn.it

I. Animal models

1. Developing competitive animal models to study Alzheimer's disease	Adalberto Merighi Adalberto.merighi@unito.it
2. Synaptic dysfunction in neurodegeneration: characterization of gene product in functional synaptic networks under physiological and patological conditions	Monica DI Luca monica.diluca@unimi.it
3. Nicotinic acetylcholine receptors, nicotine protection and neurodegenerative diseases - Neurogenesis and neurodegenerative diseases	Andrea Cavalli andrea.cavalli@iit.it
4. Development of original models for Alzheimer's Disease	Antonino Cattaneo a.cattaneo@ebri.it
5. Study of early onset Alzheimer disease in a model for Down syndrome, the Ts65Dn mouse	Renata Bartesaghi renata.bartesaghi@unibo.it
6. Neurodegeneration	Sonia Levi Levi.sonia@hsr.it
7. Non neurotoxic activity of Beta amyloid in animal models	Stefano Govoni Stefano.govoni@unipv.it

2. PHARMACOLOGY

A. Drug Design

1. Elementary mechanisms of neurodegenerative diseases	Nino Russo nrusso@unical.it
2. Innovative drug discovery strategies for Alzheimer's disease	Carlo Melchiorre Carlo.melchiorre@unibo.it
3. Development of ligands specifically targeting the Translocator Protein 18 kDa in Alzheimer disease	Federico Da Settimo fsettimo@farm.unipi.it
4. Structural studies of acetylcholinesterases and their inibitors: implicantions for the design of new anti-alzheimer drugs	Alberto Cassetta Alberto.cassetta@ts.ic.cnr.it

B. Drug screening

1. Developemt of competitive animal models for AD-GLP grade animal facility and behavioural testing	Laura Calzà laura.calza@unibo.it
2. Anti-oxidant and neurodegenerative disease: molecular basis of action of phytochemicals in neuroblastoma-derived cell models	Michele Maffia michele.maffia@unisalento.it
3. Design, synthesis and in "vitro" biological	Alberto Gasco

charaterization of multifunctional agents targeted to Alzheimer disease	alberto.gasco@unito.it
4. Yeast model to seek for molecoles which can reduce mitochondrial mutability	Liliana Ferrero Fortunati iferrero@unipr.it
5. Correlation between differen A-beta structural forms and cell toxicity: use of natural antioxidants delivered by nanoparticles for A-beta fibrillogenesis inhibition and serviva pathway activation	Marta Di Carlo di-carlo@ibim.cnr.it

C.   Drug Delivery

1. Nanotechnology for health: application in the brain diseases	MA Vandelli Giovanni Tosi gtosi@unimore.it
2. Hybrid drug containing reservoirs for long term release in brain diseases	Angelo Montenero angelo.montenero@unipr.it
3. New nanodevices overcoming the blood-brain barrier for the therapy of Alzheimer disease	Massimo Masserini massimo.masserini@unimib.it
4. Lipid and polymeric nanostructures for drug targeting to the CNS in the tratment of neurodegenerative and Alzheimer is disease	Gaetano Giammona gaegiamm@unipa.it

D.   Novel Drugs

1.	Lamberto Maffei maffei@in.cnr.it
2. Synthesis and screening of new AChE/BuChE inhibitors	Aldo Andreani Aldo.andreani@unibo.it
3. Drug design and synthesis of therapeutic agent for neurodegenerative disorders, particularly for Alzheimer disease	Olga Bruno obruno@unige.it
4. Recombinant antibodies against A beta oligomers	Antonino Cattaneo a.cattaneo@ebri.it
5. Development of a novel therapeutic strategy for AD based on a natural variant of amyloid beta that hinders amyloidogenesis	Fabrizio Tagliavini ftagliavini@istituto-besta.it
6. Evaluation of the use of plants'compounds with anti-STAT1 and/or No-enhancing activity in the prevention/treatment of Alzheimer disease	Hisanori Suzuki hisanori.suzuki@univr.it
7. Second generation, recombinant Abeta peptide immunogens as prototype vaccines for AD treatment/prevention (active immunization approach) and as primary antigens for the production of conformation sensitive therapeutic monoclonal antivodies (passive immunization approach)	Simone Ottonello s.ottonello@unipr.it
8. Pediatric neurodegenerative diseases	Maurizio Scarpa maurizio.scarpa@unipd.it
9. Ocular NGF administration as a novel non invasive approach to protect brain-NGF target neurons that degenerative in Alzheimer's disease	Francesca Roberti f.ruberti@inmm.cnr.it
10. New symptomatic and neuroprotective terapie for parkinsons's disease	Micaela Morelli morelli@unica.it

11. Innovative neuro-reparative strategies via the implementation of endogenous neurogenesis and gliogenesis: focus on the new P2Y-like GPR17 receptor	Maria Pia Abbracchio Mariapia.abbracchio@unimi.it
12. Pharmacological modulation of adult neurogenesis	Maria Grazia Grilli grilli@pharm.unipmn.it
13. Calcium modulating drugs as therapeutic tool for Alzheimer's disease	Mounia Chami – Fabio benfenati – Dolores Del Prete Fabio.benfenati@iit.it
14.	Erica Maran Erica.maran@sissa.it

E. Non-Pharmacological Therapies

1.	Pio Enrico Ricci Bitti pioenrico.riccibitti@unibo.it
2.	Lamberto Maffei maffei@in.cnr.it
3. Physical excercise and cognitive decline	Maurizio Taglialatela m.taglialatela@unimol.it
4. New tratment strategies (non pharmacologic therapeutic strategies in neurodegenerative diseases)	Andrea Stracciari andrea.stracciari@aosp.bo.it
5. Non invasive brain stimulation an integrated approach to neurorehabilitation in Alzheimer disease	Orazio Zanetti ozanetti@fatebenefratelli.it
6.	Rosaria Rinaldi Ross.rinaldi@unisalento.it
7.	Patrizia Bisiacchi patrizia.bisiacchi@unipd.it
8.	Vania Broccoli Broccoli.vania@hsr.it
9. Neural re generation in the cerebellum: development of cell replacement strategies for the management of spinocerebellar ataxias	Gian Giacomo Consalez Giacomo.comsalez@hsr.it Ferdinando Rossi Ferdianando.rossi@unito.it
10. Physical activity programs for elderly subjects with different grades of cognitive impairment	Federico Schena Federico.schena@univr.it

F. Drug Pharmacogenetics

1. Role of pharmacogenetics to identify the personalized treatment of dementia and depression.	Alberto Pilotto Alberto.pilotto@operapadrepio.it

G. Clinical studies

1. TSPO or peripheral Benzodiazepine receptor ligands as useful tools fot diagnosis and monitoring of AD patients	Silvia Selleri

3. HUMAN/CLINICAL RESEARCH

A. Human –epidemiology/risk factors

1. Phthogenic mechanisms, early diagnosis and prevention of Parkinson's disease following pesticide intake in animal model	Gabbianelli Rosita – Cinzia Nasuti rosita.gabbianelli@unicam.it
2. Effects of traffic-related particulate matter on transcription of genes implicated in neurodegeneration	Macaela Caserta micaela.caserta@uniroma1.it
3. Cronobiology and neurodegeneration	Valerio Carelli Valerio.carelli@unibo.it
4. Gene-metal interaction as determinant of neurodegenerative diseases	Roberto Lucchini lucchini@med.unibs.it
5. Using prevention to reduce the burden of Alzheimer's disease	Stefano Mattioli s.mattioli@unibo.it
6. Construction and development of "Alzheimer-Web-GIS". Geographical correlation between Alzheimer's disease and environmental parameters. Method for mapping population-based case-control studies.	Giuseppe Mele Giuseppe.mele@unisalento.it
7. Prospective evaluation of biomarkers of inflammation in Mild Cognitive Impairment subtypes, and their role in the conversion from cognitive impairment to dementia and Alzheimer's disease	Calogero Caruso immunopatologia@unipa.it
8. Epidemiology and risk factors for Mild Cognitive Impairment, Alzheimer's disease and dementia. Population-based 7-year follow-up study.	Roberto Monastero Roberto.monastero@ki.se
9. [moved to B.5 Epidemiology genetics]	Emilio Di Maria Emilio.dimaria@unige.it
10.	Salmona Mario - Forloni Mario.salmona@marionegri.it

B. Epidemiology genetics

1. Delirium in intensive care unit (ICU): evaluation of delirium as an early prognostic event functional decline, dementia or Alzheimer disease. Study of clinical, biological and genetic/epigenetic risk factors	Rita Maria Melotti Ritamaria.melotti@unibo.it
2. Mutiple genetic profiles predictive of cognitive decline and dementia. Reserch tools for the prevention of Alzheimer's diseases.	Federico Licastro Federico.licastro@unibo.it
3. Genetic susceptibility to Alzheimer's disease and genome wide association studies	Luisa Benussi lbenussi@fatebenefratelli.it
4. Genetic susceptibility to Alzheimer's disease: biobanking	Maria del Zompo delzompo@unica.it
5. Innovative technologies finalized to the improvement of diagnostic tools for the molecular analysis of spino	Silvia Piacentini piacentini@neuro.unifi.it

	cerebellar Ataxias (SCA)	

C. Biomarkers and early diagnosis and imaging

1.	Plasma biomarkers of oxidative stress and inflammation in early detection and follow-up of dementia.	Patrizia Mecocci mecocci@unipg.it
2.	Vitamins and antioxidants in aging and neurodegenerative diseases	
3.	Phenotypic and genotypic markers of early Alzheimer's disease	Salvatore Monaco Salvatore.monaco@univr.it
4.		Rita Casadio casadio@biocomp.unibo.it
5.	Cerebrospinal fluid cytokine and chemokine levels as potential biomarkers for early diagnosis of Alzheimer's disease	Elio Scarpini elio.scarpini@unimi.it
6.	Individual evaluation of cognitive decline: definition of low cost non- invasive examination battery and implementation of a predictive algorithm to identify Mild cognitive impairment	Paolo Maria Rossini Paolomaria.rossini@afar.it
7.		Antonella Mandas amandas@medicina.unica.it
8.	Molecular imaging and genetic analysis for the early diagnosis and monitoring of Alzheimer's disease in individuals with cognitice disturbances	Alessandro Padovani padovani@med.unibs.it
9.	Study early diagnosis of Alzheimer's disease and follow up progression - Standardization of diagnostic instruments, harmonization and assessment tools	Giovanni B. Frisoni gfrisoni@fatebenefratelli.it
10.	Impiego dei markers biologici e neuro radiologici nella diagnosi differenziale precoce	Orazio Zanetti ozanetti@fatebenefratelli.it
11.	Biomarkers in Mild cognitive Impairment: genetics and biochemical and neuroimaging studies for early diagnosis.	Sandro Sorbi sorbi@unifi.it
12.	A multimodality index for early diagnosis of Alzheimer's disease	Flavio Nobili flaviomariano.nobili@hsanmartino.it
13.		Marco Leonardi Marco.leonardi@unibo.it
14.	Lexical semantic skills, APOE and neuroanatomical substrate of semantic memory in early diagnosis of Alzheimer's disease	Paolo Caffarra Paolo.caffarra@unipr.it
15.	Cognitive neuroscience of dementia: clinical and theoretical aspect	Stefano F. Cappa Cappa.stefano@hsr.it
16.		Massimo Filippi Filippi.massimo@hsr.it
17.	Studies are aimed at investigating whit PET the brain functional parameters and neurotransmission systems in neurological and psychiatric diseases	Daniela Perani Daniela.perani@hsr.it
18.	Global proteomics of human fibroblast for the identification of early biomarkers for dementia and Alzheimer's disease	Maurizio Popoli Maurizio.popoli@unimi.it

19.	Parkinsons's disease: cell models and biomarkers discovery -	Daniela Parolaro – Mauro Fasanaro daniela.parolaro@uninsubria.it

D.   Diagnosis: biomarkers

1.	Proteomics of cognitive and movement disorders: Identification of molecular mechanisms associated with disease onset and phenotypic variability of frontotemporal lobar degeneration	Roberta Ghidoni rghidoni@fatebenefratelli.it
2.	Peripheral markers of oxidative stress, excitotoxicity and abnormal protein metabolism in neurodegenerative disorders.	Carlo Ferrarese Carlo.ferrarese@unimib.it
3.	Validation and search of CSF biomarkers for the early differential diagnosis of cognitive impairment. Development of new diagnostic approaches for prion diseases in humans.	Piero Parchi Piero.parchi@unibo.it
4.	Identification of microRNAs like biomarkers for early diagnosis of Alzheimer's disease	Antonino Cattaneo a.cattaneo@ebri.it
5.	Search of pre-clinical blood based molecular markers of Alzheimer's disease. - The physiologic and pathologic effect of beta-amyloid 42	Massimo Tabaton mtabaton@neurologia.unige.it
6.	Analisi Biochimica di parametri di stress ossidativo	Gabriele Siciliano gsicilia@neuro.med.unipi.it
7.	Cognitive decline in multiple sclerosis	Laura Calzà Laura.calza@unibo.it
8.	Search of predictive markers of AD based on amplification of disease-specific amyloid-beta oligomers	Fabrizio Tagliavini ftagliavini@istituto-besta.it

E.   Diagnosis: neuropsychology

1.	Handwriting analysis as a novel diagnostic tool for Alzheimer's disease in the clinical and forensic settings	Maurizio Balestrino mbalestrino@neurologia.unige.it
2.	Amnesic Mild Cognitive Impairment: neuropsychological features and new diagnostic criteria (Dubois et Al., 2007)	Angiola Maria Fasanaro Giola.fasanaro@virgilio.it
3.		Simona Luzzi s.luzzi@univpm.it
4.		Roberto Gallassi Roberto.gallassi@unibo.it
5.	Standardisation of diagnostic criteria and diagnostic instruments, harmonization and assessment tools	Manuela Contin Manuela.contin@unibo.it
6.	Individual evaluation of cognitive decline; validation of ultrafast screening tools.	Ildebrando Appollonio ildebrando.appollonio@unimib.it

F.   Biobanking Bioinformatics

1.		Giorgio Stanta stanta@impactsnetwork.eu

2. Molecular basis of Episodic Ataxia type 2 (EA2) and Spinocerebellar Ataxia type 6 (SCA6)	Francesca Ruberti f.ruberti@inmm.cnr.it
3. Deciphering neuronal apoptosis for the amytrophic lateral scerosis	Giuseppe Nicosia nicosia@dmi.unict.it

G.   Ambient assisted living and socioeconomics

1. Home-based Empowered Living for people with dementia and Parkinson's disease	Roberto Monastero roberto.monastero@unipa.it
2. Neuro-rehabilitation and brain functional imaging: rehabilitation customization driven by best exploitation of celebral plasticity and health system sustability.	Alessandra Pedrocchi pedrocchi@biomed.polimi.it
3. Role of information and communication technology (ICT) systems to improve quality of life, quality of care and safety of older patients with cognitive decline	Alberto Pilotto alberto.pilotto@operapadrepio.it
4. A transdisciplinary orented proposal from a social sciences perspective	Vincenzo Maria Bruno Giorgino Vincenzo.giorgino@unito.it
5. Home based Empowered living for Parkinson's disease patients	Roberto Monastero Roberto.monastero@ki.se